Kallikrein Trypsin Inactivator (KTI) refers to a naturally occurring protein that plays a crucial role in regulating blood clotting and inflammation in the body. It is also known as Kininogen-1 or Kunitz protease inhibitor.
KTI is primarily found in plasma, which is the liquid component of blood. Its main function is to counteract the actions of two enzymes, kallikrein and trypsin, in order to prevent excessive clotting and inflammation. Kallikrein is responsible for breaking down the precursor molecule kininogen, leading to the production of bradykinin, a potent mediator of inflammation. Trypsin, on the other hand, is involved in the degradation of various proteins, including blood clot formation factors.
The protein structure of KTI includes a specialized domain called the Kunitz domain, which is responsible for inhibiting the activities of kallikrein and trypsin. This domain binds tightly to the enzymes, ultimately preventing them from interacting with their target molecules and exerting their effects.
The presence of KTI in the blood is essential for the maintenance of normal hemostasis and prevention of excessive inflammation. Dysregulation or deficiency of KTI can lead to various medical conditions, including increased blood clot formation, uncontrolled inflammation, and potentially severe pathological consequences.
Overall, Kallikrein Trypsin Inactivator is an important protein in the body that serves as a vital regulator of clotting and inflammation, ensuring the balance and proper functioning of these processes within the circulatory system.
